Vincristine

Indication: Malignant trophoblastic neoplasms of placenta

INN: Vincristine

Medicine type: Chemical agent

List type: Complementary

Formulations: Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate)

EML status history: First added in 2015 (TRS 994) Changed in 2021 (TRS 1035)

Sex: All

Age: Adolescents and adults

Therapeutic alternatives: The recommendation is for this specific medicine

Patent information: Patents have expired in most jurisdictions Read more about patents.

Tags: Cancer

Wikipedia: Vincristine

DrugBank: Vincristine

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.

Expert Committee report